TrojanBio
Rehovot, Israel· Est.
AI‑driven bispecific antibodies that enlist viral immunity to boost cancer immunotherapy response rates.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven bispecific antibodies that enlist viral immunity to boost cancer immunotherapy response rates.
OncologyImmunology
Technology Platform
AI‑driven design of bispecific antibodies that couple a tumor‑targeting domain with a viral‑immunity activation module to convert cancer cells into virally‑infected mimics and harness anti‑viral immune responses.
Opportunities
Leveraging AI and viral‑immunity mechanisms could unlock higher response rates across diverse solid tumors, attracting partnership and licensing interest.
Risk Factors
Early‑stage technology with no clinical data; regulatory uncertainty for novel bispecific constructs and potential safety concerns of viral‑immunity activation.
Competitive Landscape
Competes with bispecific antibody developers and AI‑driven antibody platforms; differentiation lies in the viral‑immunity activation module, which is not widely pursued by peers.